The Global Fund to Fight AIDS, Tuberculosis and Malaria has announced new agreements with pharmaceutical manufacturers to lower the cost of critical HIV treatments for the 2026-2027 period. The negotiated price reductions apply to antiretroviral (ARV) medicines, including newer, more effective regimens like dolutegravir (DTG).
These agreements are part of the Global Fund's ongoing strategy to maximize the impact of its funding by securing more affordable health commodities. Lower drug prices allow the organization and its partner countries to stretch their budgets further, potentially reaching more people in need of life-saving treatment.
The initiative directly supports the Global Fund's mission to end the epidemics of AIDS, tuberculosis, and malaria. Improved access to affordable, quality-assured medicines is a cornerstone of achieving the global 95-95-95 targets for HIV testing, treatment, and viral suppression by 2030.
The savings generated from these negotiations will be reinvested into health programs in the low- and middle-income countries that the Global Fund serves. This includes strengthening health systems and supporting community-led responses to the HIV epidemic.
